We are again speaking with Dr. John Eckardt on novel targeted agents in soft tissue sarcoma.
An inversion in chromosome 2 that juxtaposes the 5' end of the EML4 gene with the 3' end of the ALK gene, resulting in the novel fusion oncogene EML4-ALK.
Today will be speaking with Dr. John Eckardt who will be discussing the 2011 American Society of Clinical Oncology Meeting.
